Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Monocytes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    131 result(s) found for: Monocytes. Displaying page 6 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2011-005815-10 Sponsor Protocol Number: AJSEB001 Start Date*: 2012-05-31
    Sponsor Name:Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Full Title: Developmental Clinical Sciences: Does GM-CSF restore effective neutrophil function in critically ill patients?
    Medical condition: Complement mediated dysfunctional neutrophil phagocytosis in critical illness.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10061314 Neutrophil function disorder PT
    16.1 10005329 - Blood and lymphatic system disorders 10017500 Functional disorders of polymorphonuclear neutrophils LLT
    14.1 10022891 - Investigations 10061867 Neutrophil function test abnormal PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001640-56 Sponsor Protocol Number: PI12/01866 Start Date*: 2014-01-31
    Sponsor Name:Fundación Para la Investigación Biomédica de Córdoba
    Full Title: Crossover clinical trial, randomized, double blind, placebo controlled trial. Modulation of cellular mediators and repair endothelial damage in patients with chronic renal disease through inhibitio...
    Medical condition: Patients with chronic kidney disease and asymptomatic hyperuricemia on the balance of mechanisms of vascular injury and repair.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001074-30 Sponsor Protocol Number: N20MAT Start Date*: 2020-06-26
    Sponsor Name:Netherlands cancer institute (NKI) Antioni van Leeuwenhoek (AvL)
    Full Title: Neo-adjuvant nivolumab or nivolumab with ipilimumab in advanced cutaneous squamous cell carcinoma patients prior to standard of care surgery; the MATISSE trial
    Medical condition: Primary or recurrent stage III-IVA cutaneous squamous cell carcinoma of all body sites OR tage I-II cutaneous squamous cell carcinoma, only in the case of: • Presence of multifocal disease for wh...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041834 Squamous cell carcinoma of skin PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077314 Skin squamous cell carcinoma metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081136 Skin squamous cell carcinoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000709-10 Sponsor Protocol Number: UKM12_0026 Start Date*: 2014-12-19
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000497-30 Sponsor Protocol Number: FIS-VED-2017-01 Start Date*: 2018-05-28
    Sponsor Name:Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI)
    Full Title: Phase II clinical trial to evaluate the safety and efficacy of Vedolizumab combined with antiretroviral treatment to achieve functional healing in people infected with HIV-1 without previous antire...
    Medical condition: Adult patients infected with HIV and without previous antiretroviral treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004370-10 Sponsor Protocol Number: RUXO_LMMC-PRO_1401 Start Date*: 2014-03-21
    Sponsor Name:Grupo Español de Sindromes Mielodisplásicos (GESMD)
    Full Title: A phase II study of ruxolitinib (INCB018424) to evaluate efficacy and safety in Patients with Proliferative Chronic Myelomonocytic Leukemia (CMML)
    Medical condition: Proliferative Chronic Myelomonocytic Leukemia (CMML)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10054350 Chronic myelomonocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001940-25 Sponsor Protocol Number: IFG-05-2019 Start Date*: 2021-08-25
    Sponsor Name:Institut für Frauengesundheit GmbH
    Full Title: A PHASE II OPEN-LABEL STUDY FOR THE COMPREHENSIVE ANALYSIS OF PREDICTORS OF THE TREATMENT WITH PEMBROLIZUMAB AND OLAPARIB IN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2 NEGATIVE BREAST CANCER AND...
    Medical condition: patients with unresectable or metastatic HER2 negative breast cancer and a deleterious germline mutation in BRCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a homologous re...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061020 Breast cancer male PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004241-32 Sponsor Protocol Number: EDOLAS Start Date*: 2020-02-07
    Sponsor Name:SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI
    Full Title: Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression
    Medical condition: HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA <50 copies/mL
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000502-30 Sponsor Protocol Number: DKFZ-2019-001 Start Date*: 2020-03-26
    Sponsor Name:German Cancer Research Center (DKFZ)
    Full Title: Personalized Vitamin D Supplementation for Reducing or Preventing Fatigue and Enhancing Quality of Life of Patients with Colorectal Tumor: Randomized Intervention Trial
    Medical condition: Fatigue in patients with colorectal cancer (ICD codes C18-C20 and C21.8) within 12 months after a colorectal cancer therapy (surgery, chemotherapy and/ or radiation) and not optimal vitamin D status
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10082239 Cancer fatigue PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10022891 - Investigations 10062189 Vitamin D decreased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001679-27 Sponsor Protocol Number: 123456 Start Date*: 2016-02-01
    Sponsor Name:CHU-ULg
    Full Title: A PHASE I/II STUDY OF THE COMBINATION OF DEFERASIROX-VITAMIN D AND AZACITIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES (IPSS INT-2 and HIGH).
    Medical condition: MYELODYSPLASTIC SYNDROMES
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005142-21 Sponsor Protocol Number: MLN1202-2005 Start Date*: 2015-05-20
    Sponsor Name:Takeda Development Centre Europe Limited
    Full Title: A Multicenter, Randomized, Double Blind, Placebo Controlled, Proof of Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Weekly Subcutaneous MLN1202, in Improving Diabetic Nephropathy Su...
    Medical condition: Diabetic Nephropathy: Adults (age 18 - 90 years inclusive) with type 2 diabetes, an eGFR of 25-59 mL/min/1.73 m2, and with macroalbuminuria (>300 mg/g) will be randomized.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001516-30 Sponsor Protocol Number: GDX-44-007 Start Date*: Information not available in EudraCT
    Sponsor Name:GUERBET
    Full Title: Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, gadopiclenol, in pediatric patients from 2 to 17 years of ageundergoing contrast-enhanced MRI.
    Medical condition: Pediatric subjects from 2 to 17 years old scheduled to undergo routine gadolinium contrast enhanced Magnetic Resonance Imaging of Central Nervous System
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022891 - Investigations 10029817 Nuclear magnetic resonance imaging brain PT
    21.1 10022891 - Investigations 10072232 Nuclear magnetic resonance imaging spinal PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Ongoing) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-005674-61 Sponsor Protocol Number: MSB-RA002 Start Date*: 2013-09-11
    Sponsor Name:Mesoblast, Inc
    Full Title: A double-blind, randomized, placebo-controlled, multi-center, dose escalation study of a single intravenous infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in the treatment of biologic-na...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) EE (Prematurely Ended) LV (Completed)
    Trial results: View results
    EudraCT Number: 2020-001724-34 Sponsor Protocol Number: PS0020 Start Date*: 2021-03-02
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA DE (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003317-33 Sponsor Protocol Number: CyPep-1 Start Date*: 2019-12-31
    Sponsor Name:Cytovation ASA
    Full Title: A first-in-human, open-label, dose escalation followed by dose expansion phase I/IIa trial to evaluate the safety, preliminary efficacy and pharmacokinetics of intratumoral CyPep-1 monotherapy and ...
    Medical condition: Histologically or cytologically confirmed locally advanced (unresectable) or metastatic tumors (solid tumors or lymphoma) with an accessible tumor lesion for intratumoral injection of CyPep-1 that ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000225-30 Sponsor Protocol Number: DMA-Clin-199-2013-001 Start Date*: 2013-04-12
    Sponsor Name:DiaMedica USA Inc.
    Full Title: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, SINGLE DOSE AND MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PROOF OF CONCEPT OF DM-199 IN HEALTHY SUBJECTS...
    Medical condition: Diabetes Mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    16.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000346-30 Sponsor Protocol Number: CINC424XDE04T Start Date*: 2015-03-16
    Sponsor Name:Universität Leipzig
    Full Title: An open-label, multicenter study of INC424 monotherapy or in combination with azacitidine for patients with post-myeloproliferative disorders (MPD) – AML or with CMML
    Medical condition: Chronic Myelomonocytic Leukemia and secondary Acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10054350 Chronic myelomonocytic leukemia LLT
    20.0 100000004864 10028557 Myeloid leukemia, acute LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000962-14 Sponsor Protocol Number: CCM-RNT-202101 Start Date*: 2021-07-02
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005769-42 Sponsor Protocol Number: WUM-KH-AL1 Start Date*: 2023-04-13
    Sponsor Name:Warsaw Medical University/ Warszawski Uniwersytet Medyczny
    Full Title: PHASE II, MULTICENTER STUDY TO ASSESS SAFETY AND EFFICACY OF COMBINATION OF SARGRAMOSTIM WITH D-VCD THERAPY (DARATUMUMAB, CYCLOPHOSPHAMIDE, BORTEZOMIB, DEXAMETHASONE) IN UNTREATED PATIENTS WITH LIG...
    Medical condition: LIGHT CHAIN AMYLOIDOSIS (Amyloidosis AL)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10021428 - Immune system disorders 10086183 AL amyloidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002760-16 Sponsor Protocol Number: IB2015-04 Start Date*: 2015-10-19
    Sponsor Name:INSTITUT BERGONIE
    Full Title: Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly trabectedin combined with Metronomic Cyclophosphamide in Patients with Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II stu...
    Medical condition: Adult patients with unresectable locally advanced or metastatic soft-tissue sarcoma.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10039494 Sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 09:30:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA